Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/29/2022 | $14.00 → $15.25 | Buy → Neutral | Citigroup |
| 8/23/2022 | Buy → Hold | Needham | |
| 8/23/2022 | $30.00 → $15.25 | Overweight → Neutral | Cantor Fitzgerald |
| 2/25/2022 | $22.00 → $14.00 | Buy | Needham |
| 11/5/2021 | $24.00 → $22.00 | Buy | Needham |
| 8/5/2021 | $26.00 → $24.00 | Buy | Needham |
Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect
Webinar to be held Friday, September 23, 2022 @ 10 a.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Leader (KOL) webinar on Friday, September 23, 2022 from 10:00 a.m. – 11:30 a.m. Eastern Time. The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aerie's investigational TRPM8 agoni
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
4 - AERIE PHARMACEUTICALS INC (0001337553) (Issuer)
15-12G - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
S-8 POS - AERIE PHARMACEUTICALS INC (0001337553) (Filer)
Citigroup downgraded Aerie Pharma from Buy to Neutral and set a new price target of $15.25 from $14.00 previously
Needham downgraded Aerie Pharma from Buy to Hold
Cantor Fitzgerald downgraded Aerie Pharma from Overweight to Neutral and set a new price target of $15.25 from $30.00 previously
Aerie Pharmaceuticals (NASDAQ:AERI) brought in sales totaling $36.13 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 38.49%, resulting in a loss of $26.83 million. In Q2, Aerie Pharmaceuticals brought in $33.31 million in sales but lost $19.37 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Aerie P
Aerie Pharmaceuticals (NASDAQ:AERI) reported quarterly losses of $(0.27) per share. This is a 62.5 percent increase over losses of $(0.72) per share from the same period last year. The company reported $36.13 million in sales this quarter. This is a 23.25 percent increase over sales of $29.31 million the same period last year.
Upgrades According to Argus Research, the prior rating for AstraZeneca PLC (NASDAQ:AZN) was changed from Hold to Buy. For the second quarter, AstraZeneca had an EPS of $0.86, compared to year-ago quarter EPS of $0.45. At the moment, the stock has a 52-week-high of $71.70 and a 52-week-low of $55.50. AstraZeneca closed at $66.32 at the end of the last trading period. According to RBC Capital, the prior rating for The Toronto-Dominion Bank (NYSE:TD) was changed from Sector Perform to Outperform. In the third quarter, Toronto-Dominion Bank showed an EPS of $1.62, compared to $1.60 from the year-ago quarter. At the moment, the stock has a 52-week-high of $86.02 and a 52-week-low of $58.64. To
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
SC 13G/A - AERIE PHARMACEUTICALS INC (0001337553) (Subject)
Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect
Builds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon's core diluted EPS in 2024 Ad hoc announcement pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in
Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Peter F. Lang will join the Company as Chief Financial Officer, effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. "I am pleased to welcome Peter to our leadership team," said Raj Kannan, Chief Executive Officer. "His extensive e
Fellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive brings breadth of clinical development, medical affairs, strategy, and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Gary Sternberg, M.D., M.B.A., will join the Company as Chief Medical Officer (CMO), effective March 1, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. Gary is an Ophthalmologist who is fellowship trained in cornea and external disease
An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021. "On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search process, the Board was pleased to interview several strong candidates and Raj rose to the top of the list during the process. Raj brings a track record of building effective organizations and teams, launching and growing products in the U.S. and globally, buildi